LBI-1103
THERAPEUTIC AREA
SOLID TUMOR CANCER
Indications
Prostate, Breast, Lung, Head & Neck, Ovarian, Stomach Cancer
REGULATORY PATHWAY
New NDA
TARGET INDICATION
Advanced first in class immediate release second generation taxane based chemotherapy. Incorporate drug resistance & targeting sensitizers
CURRENT DEVELOPMENT STATUS
Pre-clinical formulation and batches complete, MTD animal testing in progress, optimizing dosing schedules. New immediate release patent filed in April 2019. Active pre-clinical development
NEXT DEVELOPMENT PHASE
Efficacy xenograft models, human tumors in animals. Pick best of 3 Solid Tumor Drug Candidates and perform pre-clinical development and file IND with FDA
TIME TO HUMAN BENEFIT
Human trials beginning in 1.25 years
IMMEDIATE FUNDING REQUIRED?
Yes, please inquire